Virginia Powers, PhD

Articles

Frontline Ibrutinib Showcases Long-Term OS Benefit in Older Patients With CLL

June 15th 2019

Frontline therapy with ibrutinib was successfully administered for more than 60 months in patients with chronic lymphocytic leukemia aged 65 years and older and provided improved progression-free and overall survival compared with chlorambucil.

Imetelstat Provides Durable Transfusion Independence in Lower-Risk Relapsed/Refractory MDS

June 14th 2019

Imetelstat treatment may allow patients with debilitating anemia due to myelodysplastic syndrome to remain transfusion-free for extended periods of time.

Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC

April 14th 2019

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.

Nivolumab/Ipilimumab Falls Short as Maintenance Therapy in SCLC

April 13th 2019

No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.

Update Further Supports Osimertinib in Frontline EGFR+ NSCLC

April 12th 2019

Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non–small cell lung cancer.

Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

April 12th 2019

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC

April 11th 2019

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

Subsequent Immunotherapy in Control Arm Confounds Frontline Durvalumab Data in NSCLC

April 11th 2019

The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.

Diagnosis and Management of Kidney Injury Following HSCT Refined

April 4th 2019

Kidney complications often occur following successful hematopoietic stem cell transplantation from a myriad of underlying etiologies.

Expert Provides Guidelines for Diagnosis and Management of TA-TMA

April 3rd 2019

While complex, criteria for diagnosing transplant-associated thrombotic microangiopathy following hematopoietic stem cell transplantation should be closely followed and should begin with screening.

Cyclophosphamide-Driven Efficacy in GVHD Unaffected by Matched Unrelated Donor Status

April 3rd 2019

Cyclophosphamide administered alone or in combination with other agents is an effective prophylactic treatment for graft-versus-host disease, regardless of stem cell source, conditioning intensity, or patient age in 10/10 and 9/10 human leukocyte antigen matched unrelated donor hematopoietic stem cell transplantation recipients.

Risk Factor Profile Determined for Development of Pediatric TA-TMA After HSCT

April 3rd 2019

The development of high-grade acute graft-versus-host disease following hematopoietic stem cell transplantation poses the highest risk for transplant-associated thrombotic microangiopathy in pediatric patients.

Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT

April 2nd 2019

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.

Ruxolitinib/Etanercept Combo Resolves Steroid-Refractory Acute GVHD Following Allogeneic SCT

April 1st 2019

A novel treatment of ruxolitinib combined with etanercept led to encouraging response and survival rates in patients who developed grades 3/4 steroid-resistant acute graph-versus-host disease after undergoing allogeneic stem cell transplantation.

Sequential CD19- and CD22-Directed CAR T-Cell Therapy Improves Long-Term Remission in Relapsed/Refractory B-ALL

March 28th 2019

Sequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplant.

Treosulfan Conditioning Regimen for Allogeneic HSCT Improves Survival for MAC-Ineligible AML, MDS

March 27th 2019

Treosulfan added to fludarabine demonstrated an improvement in event-free and overall survival compared with busulfan/fludarabine as a treatment for patients with acute myeloid leukaemia or myelodysplastic syndrome who are scheduled for allogeneic hematopoietic stem cell transplantation but are considered ineligible for standard myeloablative conditioning.

Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL

June 17th 2018

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma

June 17th 2018

The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML

June 17th 2018

Quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

June 16th 2018

A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.